Sentencelicense agreement with Turning Point (a company later acquired by BMS) pursuant to which we obtained an exclusive license to develop and commercialize products containing repotrectinib (AUGTYRO) as an active ingredient in all human therapeutic indications in Greater China.

ZLAB 10-Kaccession 0001704292-26-000015filed Feb 26 '26BMY

GSKGSK

Sentencelicense agreement with Tesaro, a company later acquired by GSK, pursuant to which we obtained an exclusive sublicense under certain patents and know-how of GSK (including such patents and know-how licensed from Merck, Sharp & Dohme Corp.

ZLAB 10-Kaccession 0001704292-26-000015filed Feb 26 '26GSK

INVAInnoviva

Sentenceagreement with Entasis (now a wholly owned subsidiary of Innoviva), pursuant to which we obtained an exclusive license under certain patents and know-how of Entasis to develop and commercialize Entasis's proprietary compounds, durlobactam with sulbactam (the combination, SUL-DUR also known as XACDURO) with the possibility of developing and commercializing a combination of such compounds with imipenem in all human diagnostic, prophylactic and therapeutic uses in Greater China, Korea, Vietnam, Thailand, Cambodia, Laos, Malaysia, Indonesia, the Philippines, Singapore, Australia, New Zealand, and Japan.

ZLAB 10-Kaccession 0001704292-26-000015filed Feb 26 '26INVA

NVCRNovoCure

Sentenceagreement with NovoCure, pursuant to which we obtained an exclusive license under certain patents and know-how of NovoCure to develop and commercialize any Tumor Treating Fields (OPTUNE) products in all human therapeutic and preventative uses in the field of oncology in Greater China.

ZLAB 10-Kaccession 0001704292-26-000015filed Feb 26 '26NVCR

PFEPfizer

Sentencelicense agreement with Seagen (a company later acquired by Pfizer), pursuant to which we obtained an exclusive license to develop and commercialize tisotumab vedotin (TIVDAK) in Greater China.

ZLAB 10-Kaccession 0001704292-26-000015filed Feb 26 '26PFE

VRDNViridian Therapeutics, Inc.

SentenceIn August 2025, the Company entered into a material transfer agreement ("MTA") with Zai Lab, to supply certain materials for clinical trial use.

VRDN 10-Kaccession 0001590750-26-000007filed Feb 26 '26VRDN

VRTXVertex Pharmaceuticals Inc

SentenceZai licensed povetacicept for mainland China, Hong Kong SAR, Macau SAR, Taiwan region, and Singapore, while Ono licensed povetacicept for Japan and South Korea.

VRTX 10-Kaccession 0000875320-26-000056filed Feb 13 '26VRTX

—Decipheraunlisted

Sentencelicense agreement with Deciphera, pursuant to which we obtained an exclusive license under certain patents and know-how of Deciphera to develop and commercialize products containing ripretinib (QINLOCK) in the field of prevention, prophylaxis, treatment, cure, or amelioration of any disease or medical condition in humans in Greater China.

ZLAB 10-Kaccession 0001704292-26-000015filed Feb 26 '26

—MediLinkunlisted

Sentencelicense agreement with MediLink, pursuant to which we obtained an exclusive global license to research, develop, manufacture, and commercialize MediLink's proprietary ADC targeting DLL3.

ZLAB 10-Kaccession 0001704292-26-000015filed Feb 26 '26

customer

VRDNViridian Therapeutics, Inc.

SentenceIn January 2025, Zenas BioPharma sublicensed their rights under the license agreement to Zai Lab and assigned the Manufacturing Development and Supply Agreement to Zai Lab in connection with the sublicense transaction.

VRDN 10-Kaccession 0001590750-26-000007filed Feb 26 '26VRDN

Order: filed share, then A–Z, unlisted last

Methodology

ties · implied moves · holdersMethod

Ties Implied moves Holders

Dependency

Sources

Methodology

ties · implied moves · holdersMethod

Ties Implied moves Holders